CELU News and Press, Celularity Inc. From 05/23/23

2023-05-23 08:17:51 ET Celularity ( NASDAQ: CELU ) has received a $45M purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store. This marks the first purchase order received by Celularity under its recently announced expan...

Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational stage cellular therapeutic programs Marks an important first step in Celularity’s expansion strategy into the Middle ...

2023-05-22 15:33:58 ET I’m sure if you’re on this site, you’re looking for info on the best penny stocks today. That means researching trends, analyzing data, and reading up on the latest news to formulate a thesis. In this article, we’ll do just that and bre...

Early-stage data presented at the 26 th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy with placental-derived mesenchymal-like adherent stem cells (MLASCs) results in alterations in gene and protein signatures associated with inflammation and...

2023-05-10 09:48:16 ET Celularity ( NASDAQ: CELU ) is trading 7% higher premarket following an announcement that Farouk, Maamoun Tamer, the exclusive distributor for Celularity's Halal-Certified biomaterial products in the Kingdom of Saudi Arabia, is expected to submit purchas...

Celularity has been advised by the Tamer Group to expect at least $60 million to $80 million in 2023 purchase orders for Celularity's branded Halal-Certified biomaterial products Tamer Group is the exclusive distributor of Celularity's branded Halal-Certified biomaterial produ...

FLORHAM PARK, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’...

In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, two of four patients achieved an objective response at Day 28 In patients with measurable residual disease-positive (MRD posi...

Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commission...

2023-04-05 09:39:12 ET Celularity ( NASDAQ: CELU ) has entered into a definitive agreement with an institutional investor for the purchase and sale of 9.23M shares of its Class A common stock and warrants up to 9.23M shares at a combined purchase price of $0.65/share. The ...